Introduction: The development of new antimalarial drugs is time-consuming and costly, thus repurposing of drugs with initial indications for possible antimalarial indication is imperative. This study assessed the antiplasmodial effect of ketotifen (KT) in combination with artemether/lumefantrine (A/L) in Plasmodium bergei infected mice. Materials and Methods: Adult mice (25-30g) were parasitized with Plasmodium berghei, grouped, and treated per oral (p.o) with KT (0.1mg/kg), A/L (2.3/13.7mg/kg), and KT/A/L daily in curative, suppressive and prophylactic studies. The negative control (NC) and the positive control (PC) were treated daily p.o with normal saline (0.2mL) and chloroquine (CQ) (10mg/kg) for 4 days respectively. After treatment, blood samples were collected and assessed for percentage parasitemia level, hematological and lipid parameters. Results: The curative, suppressive and prophylactic studies showed significant decreases in percentage parasitemia levels at KT (0.1mg/kg) (p<0.01), A/L (2.3/13.7 mg/kg) (p<0.001) and KT/A/L (p<0.0001) when compared to negative control. Significant increases in mean survival times occurred at KT (0.1 mg/kg) (p<0.01), A/L (2.3/13.7mg/kg) (p<0.001) and A/L/T (p<0.0001) when compared to negative control. Significant increases in pack cell volume, red blood cells, hemoglobin, high-density lipoprotein cholesterol levels with significant decreases in total cholesterol, white blood cells, low-density lipoprotein cholesterol, and triglyceride levels at KT (28.6 mg/kg) (p<0.05), A/L (2.3/13.7mg/kg) (p<0.01) and KT/A/L (p<0.001) when compared to negative control. Conclusion: KT may be repurposed in combination with A/L for malaria treatment.
Georgewill, Udeme O.; Ezerioha, Chidi E.; and Adikwu, Elias
"Antiplasmodial Activity of Ketotifen-Artemether-Lumefantrine on Plasmodium Berghei Infected Mice,"
Health Sciences: Vol. 1:
1, Article 9.
Available at: https://doi.org/10.15342/hs.2020.245
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.